Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-19

Excellent 4C results showing Revenue growth is exceptional and Clinuvel on track to make $65 - $75 Million in Revenues this Financial Year - and the next 2 quarters are the really big ones for banking cash! Very pleasing to see that in the same qtr last year (leading into the 2 biggest quarters) spending on product manufacturing was $900K and this year it was $2.9 Million - a very impressive 200% increase indicating strong sales expected as well as spending towards ongoing clinical trials and perhaps even topicals. Excellent signs and 100% profit growth banked despite the increase. The next quarterly will be fantastic I expect and more importantly the full years results in less than 4 months will be the best ever for CUV.

Once again the financial fundamentals of CUV are peer leading and not matched by any peer Healthcare stock on the ASX. Anyone following Clinuvel here would realise your recent commentary regarding CUV is embarrassing to yourself@PigsMightFly, you often use the word moronic to describe others commentary but when you invent an 'average' quarterly result to pretend CUV delivered a drop in profits today there is no other way to describe that. Your motives are clearly to downramp this stock and constant lies and falsehoods are required from you to do so. Not one peer Biotech on the ASX is running such a secure and profitable business with a targeted addressable market anything like Clinuvel but you spend your time attacking this company alone. Only someone who is short CUV would do that. MSB, IMU, PNV, TLX and others all have similar market caps or greater than CUV (all theoretically have infinite P/Es) all trade with such valuations on the 'hope' of one day delivering a profit for shareholders as they progress their clinical programs. Most of these companies burn at least as much cash as CUV makes in profits. Not one has a 'cash cow' proof of concept indication to fund expansion, or an absolute market monopoly, and yet you come to CUV to scare with falsehoods and not one of the other companies receives your attention when the risk would seem to be enormously higher? You even compared CUV to companies more than 100 times larger (with much lower growth) to make another embarrassing post for yourself. All Very weird.

All IMO DYOR